Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled Phase 3 study of VY-AADC in patients with Parkinson's disease

Trial Profile

A randomized, placebo-controlled Phase 3 study of VY-AADC in patients with Parkinson's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VY AADC (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2018 New trial record
    • 17 Jul 2018 According to a Voyager Therapeutics media release, based on the feedback from a Type 2 meeting with the US FDA, the company plans to submit review a biologics license application (BLA) for VY-AADC based on the data of phase 2 study (297013). However, if the result from this study is supportive and did not met its primary endpoint, the BLA application will be also supported by this study, if able to achieve primary endpoint.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top